{"id":96602,"date":"2026-08-03T19:42:10","date_gmt":"2026-08-03T19:42:10","guid":{"rendered":"https:\/\/www.europesays.com\/britain\/96602\/"},"modified":"2026-08-03T19:42:10","modified_gmt":"2026-08-03T19:42:10","slug":"astrazeneca-investors-punish-firm-over-reports-of-400-billion-bristol-myers-pharma-deal","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/britain\/96602\/","title":{"rendered":"AstraZeneca investors punish firm over reports of $400-billion Bristol Myers pharma deal"},"content":{"rendered":"

Open this photo in gallery:<\/a><\/p>\n

AstraZeneca’s North America headquarters in Wilmington, Delaware in March, 2021.Rachel Wisniewski\/Reuters<\/p>\n

AstraZeneca AZN-N<\/a> investors punished the pharmaceutical firm on Monday over reports of merger talks with U.S. rival Bristol Myers Squibb that could make one of the world\u2019s biggest drugmakers with a combined value of nearly US$400-billion.<\/p>\n

Shares in AstraZeneca closed down some 9 per cent, the biggest drop since 2020, as investors and analysts said Britain\u2019s biggest drugmaker had little need for a transformative acquisition despite potential cost benefits. Bristol Myers shares slipped less than 1 per cent in early trading.<\/p>\n

A deal, if confirmed, would create the world\u2019s fourth-largest drugmaker by market value and the largest by revenue, in potentially one of the biggest M&A deals ever, combining a top European pharmaceutical firm with a major U.S. rival.<\/p>\n

An AstraZeneca spokesperson declined to comment on Monday. Bristol Myers, which is headquartered in New Jersey, did not respond to a request for comment.<\/p>\n

\u201cThe only advantage for AstraZeneca in this rumoured combination with BMS seems to be to accelerate its U.S. footprint and sales,\u201d said Lucy Coutts, investment director at JM Finn, an AstraZeneca shareholder.<\/p>\n

\u201cOn balance, BMS shareholders would be the winners of any combination with AZN and so this news will undoubtedly be received coolly by AZN shareholders.\u201d<\/p>\n

A person familiar with the matter told Reuters that AstraZeneca and Bristol had held talks, confirming an earlier Financial Times report. On Friday, the two had a combined market capitalization of nearly US$400-billion, with AstraZeneca valued at US$264-billion and Bristol Myers at US$133-billion.<\/p>\n

AstraZeneca forecasts steady growth in 2026 on cancer drug demand, hikes dividend<\/a><\/p>\n

Analysts and investors questioned the logic of a deal for AstraZeneca, which has been one of the most successful companies in the sector under CEO Pascal Soriot\u2019s 14 years at the helm.<\/p>\n

Markus Manns, portfolio manager at Union Investment, an AstraZeneca shareholder, said a deal \u201cdoes not make strategic or financial sense\u201d and that it would disrupt a \u201cwell-run company with a full pipeline.\u201d<\/p>\n

\u201cIf the merger rumours prove to be true, this would represent the pharmaceutical industry\u2019s equivalent of the FIFA privatization moment,\u201d added Manns, referring to FIFA\u2019s now abandoned plans to sell off a World Cup stake. \u201c(That is to say a) poorly conceived proposal that would be met with considerable bewilderment by many market participants.\u201d<\/p>\n

Lukas Leu, portfolio manager at AstraZeneca shareholder ATG Healthcare, said a deal could boost margins through cost synergies and expand reach in neuroscience and cell therapy, but questioned how a combined firm would position competing drugs.<\/p>\n

\u201cI am not a big fan of mega-mergers, it kills innovation and agility, and would be growth-dilutive for AstraZeneca in the near term,\u201d he said.<\/p>\n

One attraction for AstraZeneca could be further expanding its presence in the United States, already its biggest market.<\/p>\n

AstraZeneca this year completed a direct listing on the New York Stock Exchange, and a Bristol Myers deal would effectively mean a British company buying a major U.S. pharmaceutical champion.<\/p>\n

Bristol Myers derives the majority of its revenue from the U.S., where it has one of the largest commercial footprints.<\/p>\n

A portfolio manager at a top-20 AstraZeneca shareholder, who commented on condition of anonymity, said that while \u201cthere may be an appeal to increasing U.S. exposure,\u201d such a deal \u201cwould be a surprise given Astra management has consistently backed the business to grow organically through R&D delivery.\u201d<\/p>\n

\u201cConsensus is that Astra has a stronger pipeline and less patent expiry pressure than BMS, so why dilute that and reduce the growth outlook?\u201d<\/p>\n

Since U.S. President Donald Trump returned to office, AstraZeneca has invested tens of billions of dollars in U.S. manufacturing and cultivated close ties with the administration as the company pursues an ambitious goal of generating half of its targeted US$80-billion in annual revenue by 2030 from the U.S. market.<\/p>\n

It generated about US$59-billion in revenue last year.<\/p>\n

Sean Conroy, an analyst at Shore Capital, said a deal could also help AstraZeneca address the patent cliff it faces after 2030 and strengthen its oncology business, although he cautioned that investors were \u201cnot often fans of mega mergers of this ilk.\u201d<\/p>\n

He added that overlap between Bristol Myers\u2019 Opdivo and AstraZeneca\u2019s Imfinzi, which are the same type of cancer immunotherapy drugs, could attract antitrust scrutiny.<\/p>\n","protected":false},"excerpt":{"rendered":"Open this photo in gallery: AstraZeneca’s North America headquarters in Wilmington, Delaware in March, 2021.Rachel Wisniewski\/Reuters AstraZeneca AZN-N…\n","protected":false},"author":2,"featured_media":96603,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[20662],"tags":[5564,5555,11153,5420,345,5547,5565,1193,5546,5560,5561,5557,5548,5545,254,28,528,5559,5553,5576,5549,5550,181,5556,424,2441,5566,5551,5571,5572,5574,5569,5573,5567,5570,2843,5562,5563,14,654,5568,5554,1426,104,5558,5552,46,5575],"class_list":["post-96602","post","type-post","status-publish","format-standard","has-post-thumbnail","category-astrazeneca","tag-alberta","tag-arts-news","tag-astrazeneca","tag-bc","tag-breaking-news","tag-breaking-news-video","tag-british-columbia","tag-canada","tag-canada-news","tag-canada-sports","tag-canada-sports-news","tag-canada-trafficcanada-weather","tag-canadian-breaking-news","tag-canadian-news","tag-economy","tag-education","tag-environment","tag-federal-government","tag-foreign-news","tag-globe-and-mail","tag-globe-and-mail-breaking-news","tag-globe-and-mail-canada-news","tag-government","tag-life-news","tag-lifestyle","tag-local-news","tag-manitoba","tag-national-news","tag-new-brunswick","tag-newfoundland-and-labrador","tag-northwest-territories","tag-nova-scotia","tag-nunavut","tag-ontario","tag-pei","tag-photos","tag-political-news","tag-political-opinion","tag-politics","tag-politics-news","tag-quebec","tag-sports-news","tag-technology","tag-travel","tag-trudeau","tag-us-news","tag-world-news","tag-yukon"],"share_on_mastodon":{"url":"","error":"Validation failed: Text character limit of 500 exceeded"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/96602","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=96602"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/96602\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/96603"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=96602"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=96602"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=96602"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}